Company: NCNA
Filing Date: 2025-06-27
Form Type: 424B5
Source: 0001193125-25-151464
Chunk: 0

Company: NuCana plc
Filing Date: 2025-06-27
Form: 424B5
Chunk 0
---
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-281576

NuCana plc $100,000,000 American Depositary Shares representing Ordinary Shares We have entered into a sales agreement, or the Sales Agreement, with A.G.P./Alliance Global Partners, or A.G.P., and Laidlaw & Company (UK) Ltd., or Laidlaw, relating to the sale of American Depositary Shares, or ADSs, each ADS representing 25 ordinary shares, nominal value £0.0004 per share, or the ordinary shares, offered by this prospectus supplement. In accordance with the terms of the Sales Agreement, we may offer and sell our ADSs having an aggregate offering price of up to $100.0 million from time to time through A.G.P. and Laidlaw acting as our sales agents, or the Sales Agents. Our ADSs are listed on The Nasdaq Capital Market under the symbol “NCNA”. On June 26, 2025, the last reported sale price of our ADSs was $0.0826 per ADS. Sales of our ADSs, if any, under this prospectus supplement will be made in sales deemed to be “at the market offerings” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. The Sales Agents are not required to sell any specific amount of securities, but will act as our Sales Agents using commercially reasonable efforts consistent with their normal trading and sales practices, on mutually agreed terms between the Sales Agents and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. The compensation to the Sales Agents for sales of ADSs sold pursuant to the Sales Agreement will be an amount equal to 3.0% of the gross proceeds of any ADSs sold under the Sales Agreement. We have also agreed to reimburse the Sales Agents for certain offering related expenses. See “Plan of Distribution” beginning on page S-5of this prospectus supplement for more information. In connection with the sale of the ADSs on our behalf, each of the Sales Agents will be deemed to be an “underwriter” within the meaning of the Securities Act and the compensation of the Sales Agents will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to the Sales Agents with respect to certain liabilities, including liabilities under the Securities Act or the Securities Exchange Act of 193